From bottlenecks to breakthroughs with biotech AI

In the early days of medicine, breakthroughs came slowly. Penicillin took more than a decade to make the leap from petri dish to clinical use. The human genome, once sequenced at a cost of $2.7 billion over 13 years, now takes only a few hours and roughly $200.

Indeed, the pace of innovation today is measured in months, not decades. At Children’s Hospital of Philadelphia and Penn Medicine, a team developed and delivered a customized gene-editing treatment within six months under an early-stage compassionate-use protocol: a once unthinkable milestone that showcases rapid innovation.

AI & ML investments pay off, speeding novel solutions

In healthcare, the safeguards and systems built to protect us are often the slowest to evolve. Innovation is hampered by regulatory risk, scientific uncertainty, and prohibitive costs. All of that is changing with the power of AI.

Artificial intelligence has matured to become one of the most potent tools biotech has ever known. Algorithms aren’t just organizing health records; they’re predicting clinical outcomes. Platforms are personalizing medicine. And, within our investment portfolio, companies such as Quris AI, Centrexion Therapeutics, and Antidote Health are proving that AI can accomplish in months what previously took years.

Quris AI: Tackling 89% failure in drugs with AI

Based in Boston and Tel Aviv, Quris AI has built the world’s first Bio-AI clinical-prediction platform to ensure the safety of new drugs. The AI innovator is revolutionizing drug development by testing thousands of novel drugs on hundreds of miniaturized “patients-on-a-chip.” 

With a fully automated, self-training AI platform, Quris AI can confirm drug safety and viability far in advance of clinical testing, so that time, resources, and budget are spent on the most promising drugs to deliver them to patients faster.

Quris AI’s work isn’t just a pharma evolution, it’s a pivotal shift in how drugs reach patients. In one striking example, their platform flagged liver toxicity in a drug that had already passed animal and early human trials, highlighting a failure missed by conventional models. Recognizing its potential to prevent costly late-stage failures and improve patient safety, leading organizations are taking note.

Merck KGaA, a leading science and technology company, has adopted the platform, validating its promise and value in addressing needs and new regulatory requirements, such as the FDA Modernization Acts 2.0 and 3.0 which calls for advanced technologies rather than ineffective animal testing.

Centrexion Therapeutics: AI-powered innovation in chronic pain relief

More than one billion people endure chronic pain worldwide each year. In the United States alone, 40 million adults face this epidemic, more than those navigating cancer, diabetes and heart disease combined. 

Relief has come with risk, primarily addiction to pain relief drugs. But Centrexion Therapeutics is using AI-driven insights to develop non-opioid alternatives, accelerating the path from discovery to validation. Backed by a $40.5 million raise from investors including Lilly, Centrexion Therapeutics exemplifies how AI can de-risk development and fast-track delivery in even the most complex therapeutic areas.

Antidote Health: Affordable healthcare delivered at the speed of AI

Nearly half the world lacks access to essential healthcare, burdening healthcare systems, patients, their families, and taxpayers. In the United States, more than 30 million people are uninsured, underinsured, and priced out of care. Antidote Health is determined to bring humanity back to healthcare.

Headquartered in the U.S., the company is making healthcare more affordable and accessible. Its scalable, AI-powered platform delivers quality care to patients regardless of income, insurance status, or geography. With a proprietary AI engine that can perform diagnostics, recommend treatment plans, and optimize virtual clinician workflows, Antidote is transforming how care is delivered, moving from a reactive, in-person system to a 24/7 digital front door for primary care, mental health, and chronic condition management. 

The platform dramatically reduces costs, improving and scaling access without increased overhead. Its model is not only aligned with UN Sustainable Development Goals, but also tailored for the global digital health market which is projected to grow to $946 billion by 2030. Antidote’s combination of DeepTech, telemedicine, and AI personalization positions it at the forefront of a more inclusive, innovative healthcare system, solving challenges other companies have left unaddressed.

Great promise for patients, investors, and our world

The companies reshaping biotech today are doing more than disrupting legacy systems. They’re building a new one, where drugs reach patients faster, treatment is more personalized, and care is not just accessible, but affordable. The investment case is compelling:

• The global AI-in-healthcare market is expected to exceed $187 billion by 2030.
• AI can reduce drug discovery costs by as much as up to 70%.
• Virtual care platforms cut operating expenses while scaling reach exponentially, supporting a telehealth and telemedicine market that’s projected to surpass $180 billion by 2030.

More importantly, the impact on humans can not be understated. Lives saved, pain alleviated, entire populations with access to affordable healthcare: all made possible through AI.

Investing in the global healthtech ecosystem

Biotech investments are at the cusp of a new era, as artificial intelligence, machine learning, and data science redefine what’s possible. From bottlenecks to breakthroughs, the question isn’t how AI will transform biotechnology, it’s who will lead it. 

Tau Capital is structured to accelerate pathways from validation to full commercialization. Our portfolio reflects this mindset, and our conviction that investing in the future of health isn’t just good business. It’s a moral imperative. Explore our portfolio, and contact us to learn more.